Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 2/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 2/20 | 0.31 |
| ▸ | PAK3 | O75914 | 2/20 | 0.30 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.30 |
| ▸ | PAK2 | Q13177 | 2/20 | 0.30 |
| ▸ | USP2 | O75604 | 2/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11985801 | 0.77 | BRD4 (0.41) | BRD4CYP3A4CYP1A2ALDH1A1KDM4E | |
| SCHEMBL22509486 | 0.74 | BRD4 (0.34) | BRD4APP | |
| SCHEMBL22004970 | 0.74 | HPGD (0.43) | BRD4CYP3A4ALDH1A1KDM4EHPGD | |
| SCHEMBL19701194 | 0.74 | CSNK2A1 (0.43) | BRD4CYP3A4ALDH1A1KDM4EHPGD | |
| SCHEMBL21672437 | 0.73 | BRD4 (0.38) | BRD4CYP3A4CYP1A2ALDH1A1KDM4E | |
| SCHEMBL12146427 | 0.73 | CDK8 (0.36) | BRD4 | |
| SCHEMBL16744197 | 0.71 | GPR84 (0.48) | CYP3A4CYP1A2ALOX15USP2MAPT | |
| SCHEMBL5367102 | 0.68 | PAK1 (0.38) | CYP3A4CYP1A2ALOX15PAK3PAK1 | |
| SCHEMBL12388168 | 0.68 | ALDH1A1 (0.55) | CYP1A2ALDH1A1KDM4EHPGDLMNA | |
| SCHEMBL22792806 | 0.68 | APP (0.32) | CYP3A4APPPAK3PAK1PAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2023-11-16 | — | — | US | disclosed |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | Epizyme, Inc. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20210213014-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | Epizyme, Inc. | 2021-07-15 | — | — | US | disclosed |
| US-20200317642-A1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND DERIVATIVES THEREOF | Epizyme, Inc. | 2020-10-08 | — | — | US | disclosed |
| US-20200113901-A1 | METHODS OF USING EHMT2 INHIBITORS | Epizyme, Inc. | 2020-04-16 | — | — | US | disclosed |
| US-20200054635-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | BRD4 544/4885CYP3A4 3994/4885CYP1A2 2958/4885 |
| US-20200317642-A1 | AMINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS EHMT2 INHIBITORS AND DERIVATIVES THEREOF | HNMT, EHMT2, SHMT2 | BRD4 361/4885CYP3A4 3100/4885CYP1A2 1253/4885 |
| US-20200054635-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | BRD4 544/4885CYP3A4 3994/4885CYP1A2 2958/4885 |
| US-20200113901-A1 | METHODS OF USING EHMT2 INHIBITORS | EHMT2, EHMT1, BHMT | BRD4 1038/4885CYP3A4 2958/4885CYP1A2 1159/4885 |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | EHMT2, BHMT, SHMT2 | BRD4 544/4885CYP3A4 3994/4885CYP1A2 2958/4885 |
| US-20210213014-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | EHMT2, BHMT2, BHMT | BRD4 764/4885CYP3A4 4060/4885CYP1A2 2038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.